Mirikizumab May Help Some Crohn's Patients Reach Remission
Adults with active Crohn's disease may see improved quality of life with deep remission after one year of mirikizumab treatment.
Updated on Oct. 15, 2026 in Diabetes
Live Poll
Should chronic disease treatment prioritize deep remission over simple symptom relief for your health?
A post hoc analysis of the VIVID-1 trial reveals that approximately 20 percent of patients with active Crohn's disease achieved corticosteroid-free deep remission after one year of mirikizumab treatment. Nearly 90 percent of those patients also reported significant improvements in their quality of life.
Why it matters
Achieving deep remission—defined as both clinical and endoscopic healing—is a major goal for managing Crohn's disease and preventing long-term damage. This analysis highlights that intervening earlier in the disease course, particularly before attempting other biologic therapies, may lead to higher success rates.
In the VIVID-1 phase 3 trial involving 579 mirikizumab-treated patients and 199 placebo recipients, 20.6 percent reached PRO deep remission at week 52. These findings, presented at UEG Week 2026, suggest mirikizumab's efficacy in achieving clinical and endoscopic targets.
The players
Mirikizumab
An interleukin-23p19 antagonist approved to treat inflammatory bowel conditions like Crohn's disease.
UEG Week
An annual international gastroenterology congress where clinical research and treatment advancements are presented.
The details
Mirikizumab is an interleukin-23p19 antagonist that works by selectively blocking inflammatory signals associated with the disease. The study utilized a treat-through design to measure deep remission, which required both clinical stabilization—specifically three or fewer daily stools and an abdominal pain score of one or less—and confirmed endoscopic healing. Patients who had not previously failed other biologic therapies showed a higher remission rate of 25.5 percent compared to 15.3 percent in those with prior biologic failure.
Timeline
January 2025: FDA approved mirikizumab for active Crohn's disease.
Week 52: Deep remission rates were assessed during the study.
October 17 to 20, 2026: Results were presented at UEG Week 2026.
Health Landscape
This analysis updates findings established by the VIVID-1 trial to better understand how biologic therapies move patients toward deep remission. It reflects a broader clinical shift toward targeting endoscopic healing in addition to symptom relief for long-term Crohn's disease management.
If you are managing Crohn's disease, these findings underscore the importance of discussing treatment goals—specifically deep remission—with your gastroenterologist. Be sure to ask about the potential benefits of earlier intervention and whether biologic therapies might be appropriate for your specific care plan.
The takeaway
Mirikizumab helps some patients reach both clinical and endoscopic remission, which is linked to better quality of life. Keep track of your daily stool frequency and abdominal pain levels to help your doctor gauge if your current treatment plan is meeting deep remission goals.
Further reading
Learn more about the latest research and standard of care in the Diabetes section.
Live Poll
Should chronic disease treatment prioritize deep remission over simple symptom relief for your health?
